Theralase Technologies (TLT) AI Stock Analysis

• Market Cap: C$56.43M
• Dividend Yield: N/A
• Average Volume (3M): 68.43K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.03
• Revenue Growth: -8.63%
• EPS Growth: 7.04%
• Country: CA
• Employees: 14
• Sector: Healthcare
• Sector Strength: 43
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 250,810,200
• 10 Day Avg. Volume: 80,387
• 30 Day Avg. Volume: 68,432
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 48 Neutral
• Price Target: C$0.00 ▼(-100.00% Downside)

Theralase Technologies faces significant financial difficulties, which are a major concern for investors. Despite some positive technical trends and corporate developments, the ongoing losses and negative cash flows weigh heavily on the overall evaluation. Strategic initiatives and a positive outlook in their clinical pipeline provide some hope, but financial stability remains a critical issue.

Theralase Technologies Business Overview & Revenue Model

Company Description

Theralase Technologies Inc. is a Canadian-based company that specializes in the research, development, and commercialization of laser technologies primarily used in biophotonic and light-activated therapeutic treatments. The company operates in two main sectors: healthcare and photodynamic therapy. Its core products include patented laser systems designed for pain management, tissue healing, and oncology applications, specifically targeting cancerous cells through advanced light-activated therapies.

How the Company Makes Money

Theralase Technologies generates revenue through the sale of its laser therapy systems and related accessories to healthcare providers, clinics, and hospitals. The company also earns income from the development and commercialization of its photodynamic therapy technologies, which are aimed at treating cancer. These revenue streams are supported by strategic partnerships and collaborations with research institutions and healthcare organizations to advance clinical trials and expand the market reach of its innovative therapies. Additionally, Theralase may engage in licensing agreements for its proprietary technologies, providing another potential source of income.

Theralase Technologies Financial Statement Overview

Summary

Theralase Technologies is facing significant financial challenges, marked by declining revenues, persistent losses, and negative cash flows. The company's financial position is weakened by operational inefficiencies and heavy reliance on external financing.

Income Statement

Theralase Technologies has been experiencing declining revenue over the past few years, with a notable decrease from $1,138,569 in 2022 to $1,033,431 in 2024. The company has consistently reported negative net income, indicating ongoing losses. Gross profit margins have been low and deteriorating, reflecting challenges in cost management. The negative EBITDA and EBIT margins further highlight operational inefficiencies and lack of profitability.

Balance Sheet

The balance sheet shows a weakening position, with declining total assets and stockholders' equity over the years. The debt-to-equity ratio remains low due to minimal debt, which is a positive aspect. However, the equity ratio is declining, and the return on equity is negative due to continued losses, presenting a risk to financial stability.

Cash Flow

Theralase Technologies has been consistently generating negative operating cash flow and free cash flow, indicating struggles with generating cash from core operations. Free cash flow has shown some improvement in recent years but remains negative, highlighting cash management issues. Financing activities have been the primary source of cash, which could pose a risk if external funding becomes limited.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.03M	1.07M	1.14M	780.64K	929.12K
Gross Profit	554.03K	562.13K	628.17K	309.94K	269.68K
EBITDA	-3.96M	-4.25M	-4.90M	-4.31M	-5.56M
Net Income	-4.26M	-4.57M	-5.25M	-4.42M	-5.61M
Balance Sheet
Total Assets	3.25M	3.28M	4.16M	5.94M	10.02M
Cash, Cash Equivalents and Short-Term Investments	268.76K	43.91K	1.51M	3.69M	7.88M
Total Debt	293.87K	386.88K	473.62K	35.72K	92.34K
Total Liabilities	1.18M	1.37M	1.07M	874.79K	857.13K
Stockholders Equity	2.07M	1.91M	3.09M	5.07M	9.16M
Cash Flow
Free Cash Flow	-3.35M	-4.11M	-5.20M	-4.13M	-4.61M
Operating Cash Flow	-3.33M	-4.07M	-5.13M	-4.03M	-4.45M
Investing Cash Flow	-19.97K	-37.27K	-70.41K	-100.82K	-164.58K
Financing Cash Flow	3.57M	2.65M	3.02M	-57.37K	-57.56K

Theralase Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.22
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TLT, the sentiment is Positive. The current price of 0.22 is above the 20-day moving average (MA) of 0.21, above the 50-day MA of 0.20, and below the 200-day MA of 0.23, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.57 is Neutral, neither overbought nor oversold. The STOCH value of 62.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:TLT.

Theralase Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ASG	60 Neutral	C$23.65M	―	-23.87%	―	18.97%	17.57%
PINK	49 Neutral	C$26.74M	―	-163.62%	―	245.01%	-4.91%
TLT	48 Neutral	C$56.43M	―	-291.48%	―	-8.63%	7.04%
Sector *	47 Neutral	C$212.75M	-2.12	-24.82%	3.10%	19.48%	-0.09%
THRM	45 Neutral	$3.98M	―	-224.63%	―	57.50%	16.20%
VPT	44 Neutral	C$19.20M	―	207.08%	―	267.59%	2.33%
BLO	40 Underperform	C$69.09M	―	-79.91%	―	―	-44.50%

Theralase Technologies Corporate Events

Theralase Technologies Closes Private Placement to Fund Cancer Treatment Research

Theralase Technologies Inc. has successfully closed a non-brokered private placement, raising approximately $CAN 672,627 through the issuance of 3,363,134 units. The proceeds will be used to advance their Phase II Non-Muscle Invasive Bladder Cancer clinical study, develop Rutherrin®, and for general corporate purposes. The offering is subject to final acceptance from the TSX Venture Exchange and includes related party transactions with certain insiders. The securities issued will be subject to a hold period under Canadian securities laws.

Theralase Technologies Extends Warrant Expiry to 2028

Theralase Technologies Inc. has announced the extension of the expiry date for 4,800,000 share purchase warrants from June 30, 2025, to June 30, 2028. This extension, pending final acceptance by the TSX Venture Exchange, allows the company more time to leverage these financial instruments as it continues its development of innovative therapeutics, potentially impacting its market positioning and stakeholder interests.

Theralase Completes $CAN 571,000 Private Placement to Advance Cancer Research

Theralase Technologies Inc. has successfully completed a non-brokered private placement, raising approximately $CAN 571,000 through the issuance of 2,855,000 units. The funds will be used to advance their Phase II clinical study on Non-Muscle Invasive Bladder Cancer, develop Rutherrin®, and for general corporate purposes. The offering included related party transactions, with certain insiders participating, and is subject to final acceptance from the TSX Venture Exchange.

Theralase Completes Annual Meeting, Outlines Future Goals

Theralase Technologies Inc. announced the successful completion of its Annual General and Special Meeting, where shareholders approved various resolutions. The company hosted a virtual presentation to outline strategic objectives and upcoming milestones, emphasizing its focus on accelerating the commercialization of its innovative therapeutic technologies. This development is part of Theralase’s mission to advance safe and effective treatments for cancer, bacteria, and viruses, reinforcing its commitment to stakeholders.

Theralase Technologies to Host Annual General Meeting with Virtual Engagement

Theralase Technologies Inc. has announced its upcoming Annual General and Special Meeting (AGSM) scheduled for June 11, 2025. The meeting will be held at their Toronto head office and will include a virtual presentation for shareholders unable to attend in person. This presentation will outline the company’s strategic objectives for 2025 and 2026 and provide a platform for shareholder engagement through a question and answer session. This initiative reflects Theralase’s commitment to transparency and shareholder involvement, potentially strengthening its industry position and stakeholder relations.

Theralase Reports Q1 2025 Financial Results Amid Ongoing Research Progress

Theralase Technologies reported a significant decline in revenue for the first quarter of 2025, with a 48% year-over-year decrease to $91,190. Despite increased research and development expenses to support ongoing studies, the company faced a net loss of $1,471,250. Operationally, Theralase completed two non-brokered private placements, raising funds to support its research programs. The company is advancing its Herpes Simplex Virus treatment program and has made progress in its Phase II bladder cancer study, with promising interim results showing a 62% complete response rate among patients.

Theralase to Unveil Promising Cancer Treatment Research at ASTRO 2025

Theralase Technologies Inc. is set to present groundbreaking research at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting, showcasing promising preclinical results of their drug Rutherrin®. This ruthenium-based small molecule, when activated by radiation, demonstrates a dual-action strategy against cancer by inducing immediate cytotoxicity and stimulating a durable immune response. The study highlights Rutherrin®’s potential to enhance radiation therapy effectiveness, offering a major advancement in oncologic treatment. Theralase plans to complete GLP toxicology studies in 2025, aiming to launch clinical studies in early 2026 targeting aggressive cancers such as GBM, lung, pancreatic, lymphoma, and colorectal cancers.

Theralase Unveils Promising Cancer Treatment Results with Rutherrin

Theralase Technologies has announced promising preclinical results showing that its radiation-activated drug, Rutherrin, is significantly more effective than traditional radiation therapy in destroying cancer cells. The research, which will be presented at the ASTRO 2025 Annual Meeting, highlights Rutherrin’s ability to target tumors selectively, penetrate the blood-brain barrier, and activate a sustained immune response, potentially improving patient outcomes and overcoming treatment resistance.

Theralase Advances Cancer Treatment Studies with Promising Interim Results

Theralase Technologies has made significant progress in its Study II for BCG-unresponsive non-muscle invasive bladder cancer, with 91% of patient enrollment completed. The interim clinical data shows promising results, with a strong complete response rate and no serious adverse events reported. The company plans to complete enrollment by summer 2025 and submit a New Drug Application by 4Q2026. Additionally, Theralase is exploring international partnerships for the commercialization of its Ruvidar® treatment and has completed pre-clinical research for its use in treating glioblastoma multiforme brain cancer.